TCF Stock Overview
A clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Theracryf Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0053 |
| 52 Week High | UK£0.02 |
| 52 Week Low | UK£0.0049 |
| Beta | 1.47 |
| 1 Month Change | -2.23% |
| 3 Month Change | -32.26% |
| 1 Year Change | -67.19% |
| 3 Year Change | -89.71% |
| 5 Year Change | -92.61% |
| Change since IPO | -98.51% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Oct 11
We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely
Nov 24Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Aug 06Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?
Apr 09We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate
Dec 25Shareholder Returns
| TCF | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -2.6% |
| 1Y | -67.2% | -24.5% | 2.4% |
Return vs Industry: TCF underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: TCF underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| TCF volatility | |
|---|---|
| TCF Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TCF has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: TCF's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 9 | Huw Jones | theracryf.com |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy.
Theracryf Plc Fundamentals Summary
| TCF fundamental statistics | |
|---|---|
| Market cap | UK£2.26m |
| Earnings (TTM) | -UK£2.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs TCF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCF income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£3.34m |
| Gross Profit | -UK£3.34m |
| Other Expenses | -UK£419.00k |
| Earnings | -UK£2.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0068 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TCF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Theracryf Plc is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colin Smith | Capital Access Group |
| Adam McCarter | Cavendish |